Breast Diseases Clinical Trial
Official title:
Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection
The main goal of this project is to assess the ability of a recently developed Breast Microwave Imaging (BMI) system to detect abnormalities in a human breast. These trials will be performed by recruiting fourteen volunteers that have been diagnosed with breast abnormalities using x-ray mammography. The breast presenting the abnormality will be imaged using the BMI system in a controlled and comfortable environment. As this is a feasibility study of the technology, and has the main goal to evaluate the diagnostic accuracy of this technology. The data collected from this study will be used to: (1) evaluate the overall participant experience during the BMI imaging procedure, (2) optimize the design of the BMI imaging system (both hardware and software), (3) open discussions with other medical professionals (e.g. radiologists) about the clinical feasibility of this emerging diagnostic imaging modality.
The Breast Microwave Imaging (BMI) system that will be used in this study is designed to
detect breast abnormalities using low power microwave waveforms. The system is formed by
three main components:
1. Patient bed. The volunteer will be positioned in this bed in a prone position where with
the breast to be imaged in a pendant position.
2. Instrumentation rack. This component contains all the microwave instrumentation and
motion mechanisms required to illuminate the breast using an ultrawide band waveform and
record the responses from the breast structures.
3. Control computer. This component is used to control the motion of the mechanical
components of the system and to retrieve the responses from the breast structures from
the microwave instruments and store them in an electronic format.
The system takes between 7.5 to 10 minutes to collect a three dimensional dataset from a
single breast.
The BMI system used in the study operates in the frequency range of 20 megahertz (MHz) to 9
gigahertz (GHz). Canadian safety limits for the interaction of these non-ionizing
electromagnetic waves with humans are outlined in the Health Canada publication "Safety Code
6: Limits of Human Exposure to Radiofrequency Electromagnetic Energy in the Frequency Range
from 3 kilohertz (kHz) to 300 GHz [1]. For unregulated environments, the Specific Absorption
Rate (SAR) limit set by Health Canada is 1.6 W/Kg. In the system used in this study,
radio-frequency energy is generated via the Vector Network Analyzer (VNA). If the VNA is set
at its maximum output power, which is 3.2 milliwatt (mW), the power received at 5 cm from the
antenna (which is the distance where the breast will be) was measured to be 890 microwatt,
which would yield a SAR value of 0.0196 W/kg.
References
[1] Consumer and Clinical Radiation Protection Bureau, Limits of Human Exposure to
Radiofrequency Electromagnetic Energy in the Frequency Range from 3 kHz to 300 GHz, Health
Canada, Ottawa, Ontario, 2015.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04854304 -
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
|
||
Recruiting |
NCT01678170 -
Clinical Application of Breast Blood-oxygen Functional Imaging Technology
|
N/A | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04535466 -
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
|
||
Recruiting |
NCT01917279 -
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
|
Phase 3 | |
Recruiting |
NCT01427400 -
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
|
Phase 4 | |
Completed |
NCT05665894 -
Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis
|
||
Not yet recruiting |
NCT04088110 -
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
|
Phase 2 | |
Terminated |
NCT02997540 -
Effect of Body Position and Probe Position on the Localization of Breast Mass
|
||
Terminated |
NCT01140776 -
Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy
|
N/A | |
Recruiting |
NCT04911101 -
Performance Indicators and Patient Experience in 7G and 10G Vacuum-assisted Excision of Probably Benign Breast Lesions
|
N/A | |
Completed |
NCT04554316 -
Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery
|
N/A | |
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Completed |
NCT03743259 -
To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions
|
Phase 2 | |
Recruiting |
NCT04605575 -
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
Completed |
NCT02452333 -
Oncoplastic Approach to Excisional Breast Biopsies
|
N/A | |
Terminated |
NCT01372215 -
Multi-Compression Spot Mammography
|
N/A | |
Completed |
NCT00299039 -
T3AI-Pain After Breast Surgery
|
Phase 3 |